Skip to main content
. Author manuscript; available in PMC: 2018 Sep 12.
Published in final edited form as: Int J Hyperthermia. 2017 Jul 17;34(3):284–291. doi: 10.1080/02656736.2017.1336675

Table 1.

Median doxorubicin concentration [interquartile range] measured in pancreatic tumours following different treatment regimens (n = 4 in each group).

Treatment Median doxorubicin concentration [interquartile range] (μg/g)
LTSL-Dox 0.31 [0.07–0.58]
LTSL-Dox + MR-HIFU 9.00 [2.48–15.73]
Dox 2.27 [1.35–2.89]
Dox + MR-HIFU 4.44 [3.22–6.37]